O
Osiris Therapeutics
Stem cell company, which focuses on developing and marketing products to treat medical conditions in the
About Osiris Therapeutics
Osiris Therapeutics, Inc. is a pioneering company in the field of regenerative medicine, focusing on the research, development, manufacturing, and commercialization of innovative products designed to improve patient health and lower overall healthcare costs. The company operates primarily in the orthopedics, sports medicine, and wound care markets, serving healthcare providers and patients who require advanced therapeutic solutions. Osiris has achieved commercial success with its flagship products, including the Grafix product line, Stravix, and Cartiform, which are used to treat a variety of conditions and injuries.
The company's business model revolves around continuous innovation and strategic partnerships to develop and bring to market new regenerative medicine products. By leveraging its scientific expertise and cutting-edge technology, Osiris aims to address unmet medical needs and provide effective treatments that enhance the quality of life for patients. Revenue is generated through the sale of its proprietary products to healthcare institutions, clinics, and medical professionals.
Osiris Therapeutics is committed to advancing the field of regenerative medicine through ongoing research and development efforts. The company collaborates with leading scientific and medical institutions to explore new applications and improve existing therapies. This focus on innovation ensures that Osiris remains at the forefront of the regenerative medicine industry, delivering impactful solutions that benefit both patients and the healthcare system.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1992
- Headquarters
- Columbia, United States
- Listing
- IPO 2006
- Employees
- 149
- Open positions
- None listed
- Dealroom signal
- 32.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2019 | $660M | $660M | Smith & Nephew | — |
| EARLY VCOther financing | Jul 2018 | $0 | — | Arvind Gupta · SOSV | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $143M | 0% |
| 2025 | $143M | 0% |
| 2024 | $143M | 0% |
| 2023 | $143M | 0% |
| 2022 | $143M | 0% |
| 2021 | $143M | 0% |
| 2020 | $143M | — |
Growth signals
Latest recorded traffic for Osiris Therapeutics is 760 monthly website visits, up 230.4% over the last three months. Osiris Therapeutics's team declined 24% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Arvind Gupta
SOSV
Series B and later1 investor entered at this stage
Mesoblast
Other known investors2 additional known investors
Rutgers university
Smith & Nephew
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Osiris Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Osiris Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.